Evidence map›Paper›PMID 37734838›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023

Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics.

Andrea Galbiati, Paulina Dorten, Ettore Gilardoni, Florian Gierse, Matilde Bocci, Aureliano Zana, Jacqueline Mock, Michael Claesener, Juela Cufe, Florian Büther and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Preclinical PET, PET/CT, and PET/MRI.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  3. Review
  4. Article
  5. Targeted interleukin-2 enhances the in vivo anti-cancer activity of Pluvicto™.European journal of nuclear medicine and molecular imaging · 2024
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Andrea GalbiatiResearch and Development Department, Philochem AG, Otelfingen, Switzerland.
Paulina DortenEuropean Institute for Molecular Imaging, University of Münster, Münster, Germany.
Ettore GilardoniResearch and Development Department, Philochem AG, Otelfingen, Switzerland.
Florian GierseEuropean Institute for Molecular Imaging, University of Münster, Münster, Germany.
Matilde BocciResearch and Development Department, Philochem AG, Otelfingen, Switzerland.
Aureliano ZanaResearch and Development Department, Philochem AG, Otelfingen, Switzerland.
Jacqueline MockResearch and Development Department, Philochem AG, Otelfingen, Switzerland.
Michael ClaesenerDepartment of Nuclear Medicine, University Hospital Münster, Münster, Germany.
Juela CufeEuropean Institute for Molecular Imaging, University of Münster, Münster, Germany.
Florian BütherDepartment of Nuclear Medicine, University Hospital Münster, Münster, Germany.
Klaus SchäfersEuropean Institute for Molecular Imaging, University of Münster, Münster, Germany.
Sven HermannEuropean Institute for Molecular Imaging, University of Münster, Münster, Germany.
Michael SchäfersEuropean Institute for Molecular Imaging, University of Münster, Münster, Germany.
Dario NeriDepartment of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland; and.
Samuele CazzamalliResearch and Development Department, Philochem AG, Otelfingen, Switzerland; samuele.cazzamalli@philochem.ch philipp.backhaus@ukmuenster.de.
Philipp BackhausEuropean Institute for Molecular Imaging, University of Münster, Münster, Germany; samuele.cazzamalli@philochem.ch philipp.backhaus@ukmuenster.de.
University of Münster · DEPhilochem (Switzerland) · CHUniversity Hospital Münster · DEPhilogen (Italy) · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We studied the antitumor efficacy of a combination of

Indexed as

Interleukin-2NeoplasmsAnimalsCell Line, TumorLigandsMiceProteomicsTissue DistributionTumor MicroenvironmentInterleukin-2Ligandscombination therapiesfibroblast activation proteinimmunocytokinesradioligand therapeuticstumor targeting

Identifiers

PMID37734838
PMCPMC10690118
OpenAlexW4386925895

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.